|
CA2807546C
(en)
|
2010-08-10 |
2022-08-23 |
Rempex Pharmaceuticals, Inc. |
Cyclic boronic acid ester derivatives and therapeutic uses thereof
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
EP2487159A1
(en)
|
2011-02-11 |
2012-08-15 |
MSD Oss B.V. |
RorgammaT inhibitors
|
|
WO2013033461A1
(en)
|
2011-08-31 |
2013-03-07 |
Rempex Pharmaceuticals, Inc. |
Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
|
|
WO2013064231A1
(en)
|
2011-10-31 |
2013-05-10 |
Phenex Pharmaceuticals Ag |
SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
|
|
WO2013079223A1
(en)
|
2011-12-02 |
2013-06-06 |
Phenex Pharmaceuticals Ag |
Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rorϒ, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
|
|
AU2013259737A1
(en)
*
|
2012-05-08 |
2014-10-02 |
Lycera Corporation |
Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
|
|
JP6242868B2
(ja)
*
|
2012-05-08 |
2017-12-06 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
ＲＯＲγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ［１，８］ナフチリジンスルホンアミドおよび関連化合物
|
|
US9156858B2
(en)
|
2012-05-23 |
2015-10-13 |
Rempex Pharmaceuticals, Inc. |
Boronic acid derivatives and therapeutic uses thereof
|
|
CN107007597A
(zh)
|
2012-05-31 |
2017-08-04 |
菲尼克斯药品股份公司 |
作为孤儿核受体RORγ调节物的经甲酰胺或磺酰胺取代的噻唑及相关衍生物的制药用途
|
|
US10561675B2
(en)
|
2012-06-06 |
2020-02-18 |
Rempex Pharmaceuticals, Inc. |
Cyclic boronic acid ester derivatives and therapeutic uses thereof
|
|
ES2704744T3
(es)
|
2012-06-13 |
2019-03-19 |
Incyte Holdings Corp |
Compuestos tricíclicos sustituidos como inhibidores de FGFR
|
|
JO3215B1
(ar)
|
2012-08-09 |
2018-03-08 |
Phenex Pharmaceuticals Ag |
حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
WO2014026327A1
(en)
*
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
|
|
WO2014026329A1
(en)
*
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
|
|
WO2014026328A1
(en)
*
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
|
|
WO2014026330A1
(en)
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
MX2015008627A
(es)
|
2013-01-04 |
2015-09-23 |
Rempex Pharmaceuticals Inc |
Derivados de acido boronico y usos terapeuticos de los mismos.
|
|
US9241947B2
(en)
|
2013-01-04 |
2016-01-26 |
Rempex Pharmaceuticals, Inc. |
Boronic acid derivatives and therapeutic uses thereof
|
|
US9101638B2
(en)
|
2013-01-04 |
2015-08-11 |
Rempex Pharmaceuticals, Inc. |
Boronic acid derivatives and therapeutic uses thereof
|
|
KR20150103269A
(ko)
|
2013-01-04 |
2015-09-09 |
렘펙스 파머수티클스 인코퍼레이티드 |
보론산 유도체 및 그의 치료적 용도
|
|
EA035095B1
(ru)
|
2013-04-19 |
2020-04-27 |
Инсайт Холдингс Корпорейшн |
Бициклические гетероциклы в качестве ингибиторов fgfr
|
|
EP3027616B1
(en)
*
|
2013-07-30 |
2018-01-10 |
Boehringer Ingelheim International GmbH |
Azaindole compounds as modulators of rorc
|
|
EP3041821B1
(en)
*
|
2013-09-05 |
2018-05-30 |
Boehringer Ingelheim International GmbH |
Bicylic compounds as modulators of rorgamma
|
|
CN105531274A
(zh)
*
|
2013-09-11 |
2016-04-27 |
豪夫迈·罗氏有限公司 |
作为RORc调节剂的酮-咪唑并吡啶衍生物
|
|
ES2742843T3
(es)
|
2013-10-15 |
2020-02-17 |
Janssen Pharmaceutica Nv |
Moduladores de quinolinilo de ROR(gamma)t
|
|
US9403816B2
(en)
|
2013-10-15 |
2016-08-02 |
Janssen Pharmaceutica Nv |
Phenyl linked quinolinyl modulators of RORγt
|
|
KR20160068948A
(ko)
*
|
2013-10-15 |
2016-06-15 |
얀센 파마슈티카 엔.브이. |
RORyt의 이차 알코올 퀴놀리닐 조절제
|
|
US10555941B2
(en)
|
2013-10-15 |
2020-02-11 |
Janssen Pharmaceutica Nv |
Alkyl linked quinolinyl modulators of RORγt
|
|
BR112016008215A2
(pt)
*
|
2013-10-15 |
2017-09-26 |
Janssen Pharmaceutica Nv |
moduladores de quinolinila ligados por alquila de roryt
|
|
TW201605797A
(zh)
*
|
2013-12-10 |
2016-02-16 |
葛蘭馬克製藥公司 |
作為ror伽馬調節物的雙環雜芳基化合物
|
|
CN104530014B
(zh)
*
|
2013-12-25 |
2018-03-20 |
中国科学院广州生物医药与健康研究院 |
2‑氧代‑1,2‑二氢苯并[cd]吲哚‑6‑磺酰胺类化合物及其组合物和应用
|
|
WO2015101928A1
(en)
*
|
2013-12-31 |
2015-07-09 |
Aurigene Discovery Technologies Limited |
Fused thiophene and thiazole derivatives as ror gamma modulators
|
|
EP3102576B8
(en)
|
2014-02-03 |
2019-06-19 |
Vitae Pharmaceuticals, LLC |
Dihydropyrrolopyridine inhibitors of ror-gamma
|
|
JP2017507950A
(ja)
|
2014-02-27 |
2017-03-23 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
|
|
WO2015139621A1
(zh)
*
|
2014-03-18 |
2015-09-24 |
北京韩美药品有限公司 |
4-杂芳基取代的苯甲酸或苯甲酰胺类化合物
|
|
ES2750805T3
(es)
|
2014-05-05 |
2020-03-27 |
Rempex Pharmaceuticals Inc |
Síntesis de sales de boronato y usos de las mismas
|
|
JP6523337B2
(ja)
|
2014-05-05 |
2019-05-29 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
|
|
US9896441B2
(en)
|
2014-05-05 |
2018-02-20 |
Lycera Corporation |
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
|
|
EP3139930B1
(en)
|
2014-05-05 |
2024-08-14 |
Melinta Therapeutics, Inc. |
Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
|
|
AU2015264418A1
(en)
|
2014-05-19 |
2016-11-10 |
Rempex Pharmaceuticals, Inc. |
Boronic acid derivatives and therapeutic uses thereof
|
|
WO2016003929A1
(en)
|
2014-07-01 |
2016-01-07 |
Rempex Pharmaceuticals, Inc. |
Boronic acid derivatives and therapeutic uses thereof
|
|
PT3207043T
(pt)
|
2014-10-14 |
2019-03-25 |
Vitae Pharmaceuticals Llc |
Inibidores de di-hidropirrolopiridina de ror-gama
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
GB201419015D0
(en)
|
2014-10-24 |
2014-12-10 |
Orca Pharmaceuticals Ltd |
Compounds
|
|
US9663515B2
(en)
|
2014-11-05 |
2017-05-30 |
Vitae Pharmaceuticals, Inc. |
Dihydropyrrolopyridine inhibitors of ROR-gamma
|
|
US9845308B2
(en)
|
2014-11-05 |
2017-12-19 |
Vitae Pharmaceuticals, Inc. |
Isoindoline inhibitors of ROR-gamma
|
|
US10662205B2
(en)
|
2014-11-18 |
2020-05-26 |
Qpex Biopharma, Inc. |
Cyclic boronic acid ester derivatives and therapeutic uses thereof
|
|
EP3242878B1
(en)
|
2015-01-08 |
2020-10-14 |
Impetis Biosciences Ltd. |
Bicyclic compounds, compositions and medicinal applications thereof
|
|
EP3256450B1
(en)
*
|
2015-02-11 |
2020-12-02 |
Merck Sharp & Dohme Corp. |
Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof
|
|
WO2016128908A1
(en)
|
2015-02-12 |
2016-08-18 |
Advinus Therapeutics Limited |
Bicyclic compounds, compositions and medicinal applications thereof
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
MX373169B
(es)
|
2015-02-20 |
2020-04-24 |
Incyte Holdings Corp |
Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
WO2016145298A1
(en)
|
2015-03-12 |
2016-09-15 |
The Regents Of The University Of California |
METHODS FOR TREATING CANCER WITH RORgamma INHIBITORS
|
|
US20180051041A1
(en)
|
2015-03-17 |
2018-02-22 |
Rempex Pharmaceuticals, Inc. |
Boronic acid derivatives and therapeutic uses thereof
|
|
US10849992B1
(en)
*
|
2015-04-07 |
2020-12-01 |
Alector Llc |
Methods of screening for sortilin binding antagonists
|
|
JP2018515491A
(ja)
|
2015-05-05 |
2018-06-14 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
|
|
DK3307734T3
(da)
*
|
2015-06-09 |
2020-01-27 |
Abbvie Inc |
Nukleære receptormodulatorer (ror) til behandling af inflammatoriske og autoimmune sygdomme
|
|
WO2016198908A1
(en)
*
|
2015-06-09 |
2016-12-15 |
Abbvie Inc. |
Ror nuclear receptor modulators
|
|
KR20180025894A
(ko)
|
2015-06-11 |
2018-03-09 |
라이세라 코퍼레이션 |
Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료
|
|
WO2017024018A1
(en)
|
2015-08-05 |
2017-02-09 |
Vitae Pharmaceuticals, Inc. |
Modulators of ror-gamma
|
|
CN108137585B
(zh)
*
|
2015-09-21 |
2021-10-22 |
普莱希科公司 |
杂环化合物及其应用
|
|
RU2018117503A
(ru)
*
|
2015-10-27 |
2019-11-28 |
Мерк Шарп И Доум Корп. |
ЗАМЕЩЕННЫЕ ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORγТ И ИХ ПРИМЕНЕНИЕ
|
|
WO2017075178A1
(en)
*
|
2015-10-27 |
2017-05-04 |
Merck Sharp & Dohme Corp. |
SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
|
|
AU2016344118A1
(en)
|
2015-10-27 |
2018-05-10 |
Merck Sharp & Dohme Corp. |
Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
|
|
US11008340B2
(en)
|
2015-11-20 |
2021-05-18 |
Vitae Pharmaceuticals, Llc |
Modulators of ROR-gamma
|
|
CN105412929B
(zh)
*
|
2015-11-27 |
2018-03-20 |
肖定璋 |
Il7r‑3’utr在调控维甲酸相关孤儿核受体表达中的应用
|
|
CN109071516B
(zh)
|
2015-12-15 |
2021-08-31 |
阿斯利康(瑞典)有限公司 |
新颖的化合物
|
|
US10662187B2
(en)
*
|
2016-01-21 |
2020-05-26 |
Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. |
Bruton's tyrosine kinase inhibitors
|
|
US10793566B2
(en)
|
2016-01-21 |
2020-10-06 |
Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. |
Bruton's tyrosine kinase inhibitors
|
|
TW202220968A
(zh)
|
2016-01-29 |
2022-06-01 |
美商維它藥物有限責任公司 |
ＲＯＲ－γ調節劑
|
|
US9481674B1
(en)
|
2016-06-10 |
2016-11-01 |
Vitae Pharmaceuticals, Inc. |
Dihydropyrrolopyridine inhibitors of ROR-gamma
|
|
MX389349B
(es)
|
2016-06-30 |
2025-03-20 |
Qpex Biopharma Inc |
Derivados de ácido borónico y usos terapéuticos de los mismos.
|
|
WO2018084120A1
(ja)
*
|
2016-11-01 |
2018-05-11 |
学校法人東京理科大学 |
安息香酸誘導体及び脱水縮合剤、並びにエステル及びラクトンの製造方法
|
|
JP2020111510A
(ja)
*
|
2017-03-29 |
2020-07-27 |
科研製薬株式会社 |
インダゾール誘導体及びそれを含有する医薬
|
|
JP7090639B2
(ja)
*
|
2017-04-11 |
2022-06-24 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッド |
フッ素置換されたインダゾール化合物及びその使用
|
|
IT201700041723A1
(it)
|
2017-04-14 |
2018-10-14 |
Italfarmaco Spa |
Nuovi inibitori selettivi di HDAC6
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
KR20200019176A
(ko)
*
|
2017-06-12 |
2020-02-21 |
싸이프러스 바이오-테크 컴퍼니 리미티드 |
다중-적용 곤충 기피제 첨가제
|
|
JP2020524660A
(ja)
|
2017-06-14 |
2020-08-20 |
アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ |
Ｒｏｒ−ガンマモジュレーターとして有用な２，３−ジヒドロイソインドール−１−カルボキサミド
|
|
JP2020528904A
(ja)
|
2017-07-24 |
2020-10-01 |
ヴァイティー ファーマシューティカルズ，エルエルシー |
ＲＯＲγの阻害剤
|
|
WO2019018975A1
(en)
|
2017-07-24 |
2019-01-31 |
Vitae Pharmaceuticals, Inc. |
INHIBITORS OF ROR GAMMA
|
|
CN109485595B
(zh)
*
|
2017-09-12 |
2022-05-27 |
江苏恒瑞医药股份有限公司 |
亲水性基团取代的吲哚甲酰胺类衍生物、其制备方法及其在医药上的应用
|
|
US11286270B2
(en)
|
2017-10-11 |
2022-03-29 |
Qpex Biopharma, Inc. |
Boronic acid derivatives and synthesis thereof
|
|
AU2019234574A1
(en)
|
2018-03-12 |
2020-09-03 |
Abbvie Inc. |
Inhibitors of tyrosine kinase 2 mediated signaling
|
|
EP3781576B1
(en)
|
2018-04-20 |
2024-06-12 |
Qpex Biopharma, Inc. |
Boronic acid derivatives and therapeutic uses thereof
|
|
MA52493A
(fr)
|
2018-05-04 |
2021-03-10 |
Incyte Corp |
Sels d'un inhibiteur de fgfr
|
|
CR20200590A
(es)
|
2018-05-04 |
2021-04-26 |
Incyte Corp |
Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
TWI891666B
(zh)
|
2019-10-14 |
2025-08-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之雙環雜環
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
BR112022010664A2
(pt)
|
2019-12-04 |
2022-08-16 |
Incyte Corp |
Derivados de um inibidor de fgfr
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
AU2021266715A1
(en)
|
2020-05-05 |
2022-11-17 |
Qpex Biopharma, Inc. |
Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
|
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
EP4352059A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2023232870A1
(en)
|
2022-05-31 |
2023-12-07 |
Immunic Ag |
Rorg/rorgt modulators for the treatment of virus infections like covid-19
|